Population Pharmacokinetics of Methylphenidate Hydrochloride Prolonged-Release Tablets and Relationship between Plasma Concentration and Curative Effect in Patients with Attention Deficit/Hyperactivity Disorder

目的 1.建立注意缺陷多动障碍(attentiondeficit/hyperactivitydisorder,ADHD)患者哌甲酯缓释片的群体药动学模型，考察哌甲酯缓释片群体药动学参数的分布特征，为临床合理化治疗提供重要参数。 2.探讨ADHD患者哌甲酯缓释片多次给药后的稳态血药浓度水平及其与临床疗效和不良反应之间的关系，以指导临床合理化给药。 方法 前瞻性纳入符合国际疾病诊断和分类标准第10版（internationalclassificationofdiseases-10,ICD-10）中ADHD诊断标准的患者。 1.收集服用哌甲酯缓释片治疗的78名ADHD患者的消除相稳态血药浓...AIM 1. To establish a population pharmacokinetic (PPK) model for Methylphenidate Hydrochloride Prolonged-Release Tablets(PR-MPH) in patients with Attention Deficit/Hyperactivity Disorder(ADHD), investigate the distribution of the PPK parameters, and provide important parameter for clinical rational treatment. 2. Explore the steady-state plasma concentration levels of PR-MPH after multiple dosin...学位：医学硕士院系专业：医学院_精神病与精神卫生学学号：2452011115338

黄连素对精神分裂症患者血脂水平影响的Meta分析

目的系统评价黄连素对精神分裂症患者血脂水平的影响,为精神分裂症患者血脂干预方案的选择提供参考。方法系统检索英文数据库(PubMed、PsycINFO、Embase、Cochrane Library)和中文数据库(中国期刊全..

Population pharmacokinetic modeling of methylphenidate prolonged-release tablets clearance in patients with attention deficit/hyperactivity disorder by nonlinear mixed effects modeling

目的建立注意缺陷多动障碍患者(AdHd)哌甲酯缓释片清除率的群体药动学模型。方法前瞻性收集闽南地区服用哌甲酯缓释片治疗的78例AdHd患者的消除相血药浓度(n=165),采用非线性混合效应模型(nOnMEM)法分析数据。结果最终模型为Cl(l·H-1)=254·(WT/34.7)0.663·0.884(如果合用丙戌酸钠,否则为1)·EXP(ETA(Cl)),WT为体质量(kg)。结论成功建立AdHd患者哌甲酯缓释片治疗的群体药动学模型,根据患者的生理用药资料,可估算其清除率,为制定给药方案提供依据。AIM To establish a clearance model for methylphenidate prolonged-release tablets(MPH)in patients with attention deficit/hyperactivity disorder(ADHD)by population pharmacokinetic method.METHODS Serum concentration data(n=165)in elimination phase were collected prospectively from 78 ADHD patients in south Fujian during their routine clinical treatment.Nonlinear mixed effects modeling(NONMEM)was employed to establish the population pharmacokinetic model of the MPH clearance(CL).RESULTS The final model was:CL(L·h-1)=254·(WT/34.7)0.663·0.884(if taking sodium valproate,otherwise it equaled to 1)·EXP(ETA(CL))in which WT was weight(kg).CONCLUSION A population pharmacokinetic model is established successfully and proposed to estimate the individual CL for patients taking MPH in terms of patients' characteristics and dosing history,and to establish a prior dosage regimen.福建省卫生厅青年科研课题(编号2013-2-02); 厦门市卫生局科研立项(编号3502Z20077079